319 related articles for article (PubMed ID: 10436809)
21. Immunohistochemical expression of sialyl Tn and sialyl Lewis(a) antigens in stromal tissue correlates with peritoneal dissemination in stage IV human gastric cancer.
Ikeda Y; Mori M; Kamakura T; Saku M; Sugimachi K
Eur J Surg Oncol; 1995 Apr; 21(2):168-75. PubMed ID: 7720892
[TBL] [Abstract][Full Text] [Related]
22. CA 50: a tumor marker for gastrointestinal malignancies.
Bunworasate U; Voravud N
J Med Assoc Thai; 1995 May; 78(5):255-70. PubMed ID: 7561549
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
24. Tumour markers in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Jalanko H
Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
[TBL] [Abstract][Full Text] [Related]
25. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.
Tang H; Singh S; Partyka K; Kletter D; Hsueh P; Yadav J; Ensink E; Bern M; Hostetter G; Hartman D; Huang Y; Brand RE; Haab BB
Mol Cell Proteomics; 2015 May; 14(5):1323-33. PubMed ID: 25733690
[TBL] [Abstract][Full Text] [Related]
26. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas.
Taylor OM; Cooper EH; Benson EA; McMahon MJ
Eur J Surg Oncol; 1992 Oct; 18(5):508-13. PubMed ID: 1426303
[TBL] [Abstract][Full Text] [Related]
28. Occurrence of carcinoma-associated antigen 494 in colorectal cancer tissue and in Patients' sera during metastatic disease.
Lindhorst E
Tumour Biol; 2000; 21(2):116-22. PubMed ID: 10686541
[TBL] [Abstract][Full Text] [Related]
29. [Tumor markers in the diagnosis of tumors in the subhepatic area].
Dufek V; Petrtýl J; Klener P; Chmel J
Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
[TBL] [Abstract][Full Text] [Related]
30. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
[TBL] [Abstract][Full Text] [Related]
31. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
[TBL] [Abstract][Full Text] [Related]
32. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
33. Serum tumor markers and molecular biological diagnosis in pancreatic cancer.
Sawabu N; Watanabe H; Yamaguchi Y; Ohtsubo K; Motoo Y
Pancreas; 2004 Apr; 28(3):263-7. PubMed ID: 15084968
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of novel tumour markers.
Rhodes JM
Ann Oncol; 1999; 10 Suppl 4():118-21. PubMed ID: 10436801
[TBL] [Abstract][Full Text] [Related]
35. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
36. [Tumor markers in the upper intestinal tract--stomach and pancreas].
Pointner R; Conrad F; Schwab G
Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
[TBL] [Abstract][Full Text] [Related]
37. Tumor markers in patients with pancreatic carcinoma.
Gattani AM; Mandeli J; Bruckner HW
Cancer; 1996 Jul; 78(1):57-62. PubMed ID: 8646727
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
Miyahara S; Takahashi H; Akita H; Sasaki K; Mukai Y; Iwagami Y; Hasegawa S; Yamada D; Tomimaru Y; Noda T; Wada H; Kobayashi S; Doki Y; Eguchi H
Ann Surg Oncol; 2024 May; 31(5):2932-2942. PubMed ID: 38368291
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy.
Nakaizumi A; Uehara H; Takenaka A; Uedo N; Sakai N; Yano H; Ohigashi H; Ishikawa O; Ishiguro S; Sugano K; Tatsuta M
Hepatogastroenterology; 1999; 46(25):31-7. PubMed ID: 10228761
[TBL] [Abstract][Full Text] [Related]
40. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]